Evaluating Tolerability of EPUHRT with Brachytherapy Boost

Clinicaltrials.gov ID: NCT06817668
db-list-check Status RECRUITING
b-loader Phase NA
b-people Age ≥ 18 Years
b-bullseye-arrow Enrollments 31

Conditions

Prostate Cancer

Summary

The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radiotherapy with High Dose Rate Brachytherapy Boost (form of internal radiation where a cancer doctor implants a small plastic tube or balloon (catheter) in the tumor).

Detailed Description

Progression free survival from irradiation dose escalation has been demonstrated across multiple prospective randomized studies. Irradiation dose escalation delivered by dual therapy (consisting of external beam irradiation treatment with brachytherapy boost, a type of internal radiation) offers improved survival. Brachytherapy boost makes it possible to safely deliver higher irradiation dose to the prostate gland than can be achieved with dose escalation by standard fractionated external beam treatment.

Locations

1 location Found with status Recruiting

Status

  • RECRUITING

Contact Person

Principal Investigator

  • Omar Ishaq, MD

Eligibility Criteria

Inclusion Criteria:

1. ≥ 18 years old at the time of informed consent
2. Capable of providing informed consent and HIPAA authorization
3. Karnofsky performance score ≥ 70
4. Pathologically confirmed unfavorable intermediate, high, and very high-risk prostate cancer per treating physician
5. Candidate plans to undergo the standard of care prostate high dose brachytherapy boost procedure
6. Up to date colon cancer screen per per American Cancer Society guidelines

Exclusion Criteria:

1. Prior pelvic irradiation treatment
2. Prior rectal surgery which precludes instrumentation with rectal ultrasound probe.
3. Evidence of nodal or distant disease on screening diagnostic work up.
4. Prior prostatectomy, Holmium laser enucleation of the prostate or transurethral resection of the prostate procedure
5. International Prostate Symptom Score (IPSS) score > 16 despite medical therapy

Study Plan

ePURT 5Gy x 5 fractions with single HDR boost of 15Gy

EXPERIMENTAL

Single arm non-randomized non-inferiority study exploring tolerability of ePURT 5Gy x 5 fractions delivered on noncontiguous weekdays with single HDR boost of 15Gy.

  • RADIATION:

    ePURT 5Gy x 5 fractions with single HDR boost of 15Gy

    Description:

    ePURT 5Gy x 5 fractions delivered on noncontiguous weekdays with single HDR boost of 15Gy.

Outcome Measures

Primary Outcome Measures

Percentage of participants with acute grade u2265 2 GU toxicity

Time Frame: 3 months

Secondary Outcome Measures

Percentage of participants with acute grade u2265 2 GI toxicity

Time Frame: 3 months

Percentage of participants with acute grade u2265 2 GU toxicity

Time Frame: 3 months

Timeline

  • Last Updated
    March 4, 2025
  • Start Date
    February 10, 2025
  • Today
    May 12, 2025
  • Completion Date ( Estimated )
    October 1, 2028

Similar Trials

light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people All Ages